Список литературы

1. Sanz M.A. et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.//Blood. 2009. Vol. 113, N 9. P. 1875 - 1891.

2. Савченко В.Г., Паровичникова Е.Н. Острый промиелоцитарный лейкоз. М.: Литерра, 2010. 200 р.

3. Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN) Guidelines. 2-2020. [Electronic resource]. URL: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.

4. Паровичникова Е.Н., Соколов А.Н., Савченко В.Г. Протокол лечения острого промиелоцитарного лейкоза AIDA//Программное лечение заболеваний крови, под ред. Савченко В.Г. 2012. P. 265 - 287.

5. Tallman M.S., Altman J.K. How I treat acute promyelocytic leukemia//Blood. 2009. Vol. 114, N 25. P. 5126 - 5135.

6. Brain B.J. Acute promyelocytic leukemia//Leukemia Diagnosis/ed. Brain B.J. Blackwell Science, 1999. P. 14 - 19.

7. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).//Leukemia. 1995. Vol. 9, N 10. P. 1783 - 1786.

8. Rowley J.D., Golomb H.M., Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia//The Lancet. 1977. Vol. 309, N 8010. P. 549 - 550.

9. Fukutani H. et al. Molecular Heterogeneity of the PML Gene Rearrangement in Acute Promyelocytic Leukemia: Prevalence and Clinical Significance//Japanese J. Cancer Res. 1993. Vol. 84, N 3. P. 257 - 264.

10. Baba S.M. et al. Influence of bcr-3 transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.//Cancer Genet. 2019. Vol. 231 - 232. P. 14 - 21.

11. Ku G.H. et al. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival//Blood. 2009. Vol. 113, N 17. P. 3911 - 3917.

12. Grimwade D. The significance of minimal residual disease in patients with t (15; 17)//Best Pract. Res. Clin. Haematol. Bailliere Tindall Ltd, 2002. Vol. 15, N 1. P. 137 - 158.

13. Chendamarai E. et al. Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.//Blood. 2012. Vol. 119, N 15. P. 3413 - 3419.

14. Ravandi F., Walter R.B., Freeman S.D. Evaluating measurable residual disease in acute myeloid leukemia.//Blood Adv. 2018. Vol. 2, N 11. P. 1356 - 1366.

15. Fang R.C., Aboulafia D.M. HIV infection and myelodysplastic syndrome/acute myeloid leukemia//HIV-Associated Hematological Malignancies. 2016. P. 133 - 144.

16. Freeman A.J. et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection.//Hepatology. 2001. Vol. 34, N 4 Pt 1. P. 809 - 816.

17. Ribas A. et al. How important is hepatitis C virus (HCV)-infection in persons with acute leukemia?//Leuk. Res. 1997. Vol. 21, N 8. P. 785 - 788.

18. Leahy M.F., Mukhtar S.A. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice.//Intern. Med. J. 2012. Vol. 42, N 3. P. 332 - 338.

19. Barbey J.T., Pezzullo J.C., Soignet S.L. Effect of arsenic trioxide on QT interval in patients with advanced malignancies//J. Clin. Oncol. 2003. Vol. 21, N 19. P. 3609 - 3615.

20. Herrmann J. et al. Evaluation and management of patients with heart disease and cancer: Cardio-oncology//Mayo Clin. Proc. 2014. Vol. 89, N 9. P. 1287 - 1306.

21. Park J.H. et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.//Blood. 2011. Vol. 118, N 5. P. 1248 - 1254.

22. Lehmann S. et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.//Leukemia. 2011. Vol. 25, N 7. P. 1128 - 1134.

23. Mantha S., Tallman M.S., Soff G.A. What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?//Curr. Opin. Hematol. 2016. Vol. 23, N 2. P. 121 - 126.

24. Mantha S. et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.//Blood. 2017. Vol. 129, N 13. P. 1763 - 1767.

25. Meijer K. et al. Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa.//Arch. Intern. Med. 2000. Vol. 160, N 14. P. 2216 - 2217.

26. Pemmaraju N. et al. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature.//Front. Oncol. 2015. Vol. 5. P. 29.

27. Li X. et al. Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis//Hematology. Taylor and Francis Ltd., 2017. Vol. 22, N 8. P. 450 - 459.

28. Fenaux P. et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.//Leukemia. 2000. Vol. 14, N 8. P. 1371 - 1377.

29. Fenaux P. et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.//Blood. 1999. Vol. 94, N 4. P. 1192 - 1200.

30. Shen Z.-X. et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.//Proc. Natl. Acad. Sci. U. S. A. 2004. Vol. 101, N 15. P. 5328 - 5335.

31. Powell B.L. et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.//Blood. 2010. Vol. 116, N 19. P. 3751 - 3757.

32. Iland H.J. et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: A non-randomised phase 2 trial//Lancet Haematol. 2015. Vol. 2, N 9. P. e357 - e366.

33. Lo-Coco F. et al. Retinoic Acid and Arsenic Trioxide for APL//N. Engl. J. Med. 2013. Vol. 369, N 2. P. 111 - 121.

34. Platzbecker U. et al. Improved Outcomes With ATRA and ATO compared with ATRA and Chemo in non-high-risk APL_Final Results of APL0406 trial//J. Clin. Oncol. American Society of Clinical Oncology, 2017. Vol. 35, N 6. P. 605 - 612.

35. Sanz M.A., Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.//Blood. 2014. Vol. 123, N 18. P. 2777 - 2782.

36. Lo-Coco F., Cicconi L., Breccia M. Current standard treatment of adult acute promyelocytic leukaemia.//Br. J. Haematol. 2016. Vol. 172, N 6. P. 841 - 854.

37. Lo-Coco F. et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group//Blood. 2010. Vol. 116, N 17. P. 3171 - 3179.

38. Sanz M.A. et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.//Blood. 2000. Vol. 96, N 4. P. 1247 - 1253.

39. Tallman M.S. et al. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol//Blood. 2002. Vol. 100, N 13. P. 4298 - 4302.

40. Montesinos P. et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.//Haematologica. 2009. Vol. 94, N 9. P. 1242 - 1249.

41. Finsinger P. et al. Acute promyelocytic leukemia in patients aged > 70 years: the cure beyond the age.//Ann. Hematol. 2015. Vol. 94, N 2. P. 195 - 200.

42. Chang A., Patel S. Treatment of Acute Myeloid Leukemia During Pregnancy//Annals of Pharmacotherapy. 2015. Vol. 49, N 1. P. 48 - 68.

43. Троицкая В.В. et al. Лечение острого промиелоцитарного лейкоза на фоне беременности//Терапевтический архив. 2013. Vol. 10. P. 56 - 63.

44. Browne H., Mason G., Tang T. Retinoids and pregnancy: an update//Obstet. Gynaecol. 2014. Vol. 16. P. 7 - 11.

45. Arsenic trioxide Pregnancy and Breastfeeding Warnings [Electronic resource]. 2018. URL: https://www.drugs.com/pregnancy/arsenic-trioxide.html#ref_pregnancy.

46. Salem M.N., Abbas A.M., Ashry M. Dexamethasone for the prevention of neonatal respiratory morbidity before elective cesarean section at term//Proc. Obstet. Gynecol. 2016. Vol. 6, N 3. P. 1 - 10.

47. Gill H. et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.//Cancer. 2018. Vol. 124, N 11. P. 2316 - 2326.

48. Lengfelder E. et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet//Leukemia. 2015. Vol. 29, N 5. P. 1084 - 1091.

49. Ganzel C. et al. Autologous transplant remains the preferred therapy for relapsed APL in CR2//Bone Marrow Transplant. Nature Publishing Group, 2016. Vol. 51, N 9. P. 1180 - 1183.

50. Ramadan S.M. et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era//Haematologica. 2012. Vol. 97, N 11. P. 1731 - 1735.

51. Furuya A. et al. Central nervous system involvement of acute promyelocytic leukemia, three case reports//Clin. Case Reports. Wiley, 2017. Vol. 5, N 5. P. 645 - 653.

52. J. et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study.//Haematologica. 2006. Vol. 91, N 1. P. 84 - 91.

53. Enno A. et al. Co-trimoxazole for prevention of infection in acute leukaemia.//Lancet (London, England). 1978. Vol. 2, N 8086. P. 395 - 397.

54. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016. 94 p.

55. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

56. Sanz M.A. et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed -positive acute promyelocytic leukemia//Blood. 1999. Vol. 94, N 9. P. 3015 - 3021.

57. Burnett A.K. et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial//Lancet Oncol. Lancet Publishing Group, 2015. Vol. 16, N 13. P. 1295 - 1305.